Oxepanoprolinamides are a class of antibiotics. They include iboxamycin.[1] These drugs are fully synthetic. The molecules contain the aminooctose component of clindamycin. They were developed by Andrew G. Myers and Yury S. Polikanov.[1] The structure contains an oxepane (a seven-membered ring compound with oxygen) and a proline, with an amide group that increases rigidity.[2]
Oxepanoprolinamides function by insertion into bacterial ribosomes. They overcome a type of antibiotic resistance to clindamycin based on Erm and Cfr ribosomal RNA methyltransferase enzymes.[1][3][4]
References
edit- ^ a b c Halford, Bethany (28 October 2021). "New class of synthetic antibiotics battle drug-resistant bacteria". Chemical & Engineering News. 99 (40).
- ^ Mitcheltree, Matthew J.; Pisipati, Amarnath; Syroegin, Egor A.; Silvestre, Katherine J.; Klepacki, Dorota; Mason, Jeremy D.; Terwilliger, Daniel W.; Testolin, Giambattista; Pote, Aditya R.; Wu, Kelvin J. Y.; Ladley, Richard Porter; Chatman, Kelly; Mankin, Alexander S.; Polikanov, Yury S.; Myers, Andrew G. (2021). "A synthetic antibiotic class overcoming bacterial multidrug resistance". Nature. 599 (7885): 507–599. Bibcode:2021Natur.599..507M. doi:10.1038/s41586-021-04045-6. PMC 8549432. PMID 34707295.
- ^ Mitcheltree, Matthew J.; Pisipati, Amarnath; Syroegin, Egor A.; Silvestre, Katherine J.; Klepacki, Dorota; Mason, Jeremy D.; Terwilliger, Daniel W.; Testolin, Giambattista; Pote, Aditya R.; Wu, Kelvin J. Y.; Ladley, Richard Porter; Chatman, Kelly; Mankin, Alexander S.; Polikanov, Yury S.; Myers, Andrew G. (27 October 2021). "A synthetic antibiotic class overcoming bacterial multidrug resistance". Nature. 599 (7885): 507–512. Bibcode:2021Natur.599..507M. doi:10.1038/s41586-021-04045-6. PMC 8549432. PMID 34707295.
- ^ "Bacterial drug resistance overcome by synthetic restructuring of antibiotics". Nature: d41586–021–02916-6. 27 October 2021. doi:10.1038/d41586-021-02916-6. PMID 34711985. S2CID 240153291.